Jubilant Life Science has got the US health regulator’s approval for Telmisartan Tablets that are used in the treatment of hypertension, in the American market.

The company has said in a BSE filing that “it has received Abbreviated New Drug Application (ANDA) final approval for Telmisartan Tablets, USP 20,40 and 80mg, the generic version of Micardis Tablets of Boehringer Ingelheim Pharmaceuticals Inc.”

Read EquityPandit’s Technical Analysis on Nifty Pharma